MétaCan
Menu
← Back to cohort
Record W4302009239 · doi:10.21203/rs.3.rs-2042183/v1

A Pilot Study about the Effectiveness of High-Dose Donepezil in Cognitive Function and Neuropsychiatric Symptoms in Parkinson’s disease with Cognitive Impairment

2022· preprint· en· W4302009239 on OpenAlexaboutno aff
Eun Joo Chung, Jin Ho Jung, Sang Jin Kim

Bibliographic record

VenueResearch Square · 2022
Typepreprint
Languageen
FieldMedicine
TopicParkinson's Disease Mechanisms and Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsDonepezilDementiaNeurocognitiveDementia with Lewy bodiesMedicineMontreal Cognitive AssessmentInternal medicineParkinson's diseaseCognitionPsychologyDiseasePsychiatry

Abstract

fetched live from OpenAlex

Abstract Background:Donepezil is used for the symptomatic treatment of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB) and Parkinson’s disease (PD) with dementia. Donepezil has been shown to improve behavioral and psychological symptoms of dementia in AD and DLB dose-dependently. We analyzed whether administration of 23 mg/day of donepezil would be more effective than 10 mg/day for both cognitive function and neuropsychiatric symptoms in PD patients with cognitive impairment (CI). Methods:Ten patients diagnosed with PD by the UK Brain Bank Criteria participated in the study. The cognitive function of patients was adequate according to the criteria for major and minor neurocognitive disorders. Among all patients already taking 10 mg/day donepezil, 3 patients increased the dose to 23 mg/day and then maintained this dose for 24 weeks. Seven of the 10 patients continued the10 mg/day dose for 24 weeks. The Korean version of mini-mental status examination (K-MMSE), Korean version of Montreal Cognitive Assessment (K-MoCA), and caregiver-administered neuropsychiatric inventory (NPI) were examined at baseline and 24 weeks. Results:Compared to the 23 mg/day group, the 10 mg/day donepezil group showed a younger age at onset and a longer disease duration at baseline. The K-MMSE and K-MoCA scores were higher in the 10 mg/day group than in the 23 mg/day group at baseline. However, the K-MMSE and K-MoCA of the donepezil 23 mg/day group after 24 weeks showed more improvement than those of the donepezil 10 mg/day group. In eight patients who performed the NPI, mood disorders (depression, anxiety, apathy) frequently appeared at both baseline and 24 weeks, in contrast to psychosis (delusion and hallucination). Conclusions:Compared to 10 mg/day donepezil, 23 mg/day donepezil was more effective in improving cognitive function in PD in a dose-dependent manner. Total scores in NPI showed a worse outcome in the 10 mg/day group after 24 weeks, despite being younger and having less severe parkinsonism compared to the 23 mg/day group. Because psychosis was frequent in PD with dementia, high rates of mood disorders and low rates of psychosis were associated with PD with cognitive impairment in this study.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.348
Teacher spread0.314 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueResearch Square→Same topicParkinson's Disease Mechanisms and Treatments→French-language works237,207→